Key facts
- Notable investors include Green Pine Capital Partners, Qianhai Xinghe Capital, Shenzhen Lihe Science and Technology Innovation.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Sinobio
- ·The full record, as it builds
Funding rounds
No funding rounds for Sinobio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sinobio
Developer of recombinant biopharmaceuticals designed to advance therapeutic and aesthetic applications through synthetic biology. The company offers proprietary protein engineering platforms, high-throughput screening technologies, and patented manufacturing processes, enabling clinical researchers and aesthetic practitioners to access safer, purer and more consistent botulinum-based treatments.
- Sector
- Healthcare
- HQ
- Shenzhen, China
- Founded
- 2024
- Ownership
- Privately Held (backing)
Sinobio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sinobio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sinobio in its N-PORT filings yet. We sweep new filings monthly.